Ana Callejo

Burgos, CL, ES 
Burgos, CL, ES 

Overview

Ana Callejo practices practicing medicine in Burgos, Spain.

Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Herpes Simplex Encephalitis, and Mesothelioma.

She is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Burgos, CL, Spain
Other Locations
Barcelona, CT 08035, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Durvalumab, Carboplatin, Paclitaxel
Study Phase: Phase 2
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Brigatinib
Study Phase: Phase 2
View 1 Less Clinical Trial

23 Total Publications

Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment.
Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment.
Journal: Genome medicine
Published: November 07, 2025

Frequently Asked Questions about Ana Callejo

Is Ana Callejo a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Ana Callejo is classified as an Experienced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ana Callejo participate in research or clinical trials?

Yes. Ana Callejo has published 23 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Ana Callejo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Callejo's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile